<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01623661</url>
  </required_header>
  <id_info>
    <org_study_id>EBP-JMJ-2012-2</org_study_id>
    <nct_id>NCT01623661</nct_id>
  </id_info>
  <brief_title>Effect of Hypertonic Sodium Chloride on Urinary Biomarkers in Healthy Subjects and Patients With Chronic Kidney Disease</brief_title>
  <acronym>CASE</acronym>
  <official_title>Effect of Intravenous Sodium Chloride on Urinary Biomarkers for Measurement of Sodium- and Water Channel Activity in the Nephron in Healthy Subject an Patients With Chronic Kidney Disease. A Case Control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regional Hospital Holstebro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regional Hospital Holstebro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with chronic kidney disease (CKD) have a defect in the tubular reabsorption of&#xD;
      sodium, and therefore the ability to excrete a sodium load is diminished compared to healthy&#xD;
      subjects.&#xD;
&#xD;
      Urinary biomarkers reflects the water- and sodium-channel activity in the kidney and may be&#xD;
      measured after an infusion with hypertonic saline in CKD patients and healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The fractional sodium excretion is elevated as high as 10-20% In patients with chronic kidney&#xD;
      disease (CKD) Changes in the sodium intake results in a slower expansion and/or reduction in&#xD;
      extracellular fluid in CKD patients.&#xD;
&#xD;
      Urinary biomarkers reflects the kidneys transport of sodium and water in the nephron.&#xD;
&#xD;
      Changes in the sodium-and water channel activity is induced by intervention with hypertonic&#xD;
      Saline (3.0%) The change in sodium-and water channel activity is followed by change in&#xD;
      extracellular and intracellular fluid compartments and the plasma concentration of vasoactive&#xD;
      hormones.&#xD;
&#xD;
      The purpose of this study is to investigate the changes in urinary biomarkers (u-NKCC2,&#xD;
      u-ENaC-gamma and u-AQP2), the activity of the sodium-and water channels, the extra- and&#xD;
      intracellular fluid compartments and the plasma concentration of Vasoactive hormones in&#xD;
      patients with CKD and in healthy subjects.&#xD;
&#xD;
      Subjects and patients are examined during one examination day. Four days prior to the&#xD;
      examination day the subjects consume a standardized diet based on the amount of sodium and&#xD;
      calories. On the examination day the subjects receive an infusion with hypertonic saline.&#xD;
&#xD;
      Renal function is measured by renal clearance of 51Cr-EDTA. Urinary biomarkers (u-NKCC2,&#xD;
      u-ENaC-gamma and u-AQP2) are measured to evaluate the activity of sodium channels in the&#xD;
      nephron and changes in fluid compartments are measured by body composition monitor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>urinary biomarkers</measure>
    <time_frame>one day</time_frame>
    <description>Urinary epithelial sodium channels (ENaC), Sodium-potassium-2chloride transporters (NKCC) and aquaporin2 channels (AQP2) before, during and after fluid infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>vaso active hormones</measure>
    <time_frame>one day</time_frame>
    <description>plasma concentrations of: renin, Angiotensin II, aldosterone, Vasopressin, atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>extra-and intracellular volume</measure>
    <time_frame>6 hours</time_frame>
    <description>measured by body composition monitor at baseline and after intervention</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Nephropathy</condition>
  <arm_group>
    <arm_group_label>hypertonic saline</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>hypertonic saline 3.0% (7 ml/kg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>hypertonic saline</intervention_name>
    <description>hypertonic saline 3.0 % (7 ml/kg)</description>
    <arm_group_label>hypertonic saline</arm_group_label>
    <other_name>hypertonic NaCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. healthy subjects&#xD;
&#xD;
               -  healthy males and females&#xD;
&#xD;
               -  age 18-70&#xD;
&#xD;
               -  BMI range 18,5-30,0 kg/m2&#xD;
&#xD;
          2. Patients with CKD&#xD;
&#xD;
               -  age 18-70&#xD;
&#xD;
               -  eGFR 15-60 ml/min&#xD;
&#xD;
               -  BMI range 18.5 - 30.0 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. healthy subjects&#xD;
&#xD;
               -  hypertension (ie ambulatory BP &gt;130 mmHg systolic or/and &gt;80 mmHg diastolic)&#xD;
&#xD;
               -  history or clinical significant signs of heart, lung, liver, kidney, endocrine,&#xD;
                  brain or neoplastic disease.&#xD;
&#xD;
               -  alcohol abuse&#xD;
&#xD;
               -  drug abuse&#xD;
&#xD;
               -  smoking&#xD;
&#xD;
               -  pregnancy or nursing&#xD;
&#xD;
               -  blood donation within a month prior to examination&#xD;
&#xD;
               -  Medical treatment apart from oral contraception&#xD;
&#xD;
          2. Patients with chronic kidney disease&#xD;
&#xD;
               -  clinical significant signs of heart, lung, liver, endocrine, brain or neoplastic&#xD;
                  disease.&#xD;
&#xD;
               -  diabetes&#xD;
&#xD;
               -  immunosuppressive medications&#xD;
&#xD;
               -  smoking&#xD;
&#xD;
               -  alcohol abuse&#xD;
&#xD;
               -  drug abuse&#xD;
&#xD;
               -  pregnancy or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erling B Pedersen, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Regional Hospital Holstebro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Research</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>June 18, 2012</study_first_submitted>
  <study_first_submitted_qc>June 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2012</study_first_posted>
  <last_update_submitted>March 3, 2014</last_update_submitted>
  <last_update_submitted_qc>March 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Regional Hospital Holstebro</investigator_affiliation>
    <investigator_full_name>Erling Bjerregaard Pedersen</investigator_full_name>
    <investigator_title>DMSc</investigator_title>
  </responsible_party>
  <keyword>Nephrology</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>sodium-channels</keyword>
  <keyword>water-channels</keyword>
  <keyword>BCM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

